Kitahama Takumi, Gomyo Yoshihito, Okada Ichiro, Akita Noriyuki, Ikeno Tatsuo, Miyamoto Hideo
Dept. of Surgery, Shinonoi General Hospital.
Gan To Kagaku Ryoho. 2019 Apr;46(4):709-712.
The patient was a 79-year-old man. He had ascending colon carcinoma and multiple hepatic metastases, and right hemicolectomy( D2)was performed in June 2012(SE, N1, P0, M1[H3], Stage Ⅳ). After surgery, 8 courses of mFOLFOX6 plus panitumumab biweekly, then, 5-FU/l-LV biweekly and panitumumab every 4 weeks were administered because he had wild- type KRAS. Before chemotherapy, his serum CEA level was 122 ng/mL, but the value decreased rapidly to a normal level after 7months. The hepatic metastases also decreased, and the lesion was only slightly observed on CT after 7months. Five years after the surgery, images and his CEA level are both normal, and the effectiveness is maintained. Even for right colon cancer, anti-EGFR antibodies might be effective if RAS is wild-type.
该患者为一名79岁男性。他患有升结肠癌并伴有多处肝转移，于2012年6月进行了右半结肠切除术（D2）（SE，N1，P0，M1[H3]，Ⅳ期）。术后，由于他具有野生型KRAS，给予了8个疗程的mFOLFOX6联合帕尼单抗，每两周一次，然后，每两周给予5-FU/亚叶酸钙，每4周给予一次帕尼单抗。化疗前，他的血清癌胚抗原（CEA）水平为122 ng/mL，但7个月后该值迅速降至正常水平。肝转移灶也有所减少，7个月后在CT上仅轻微可见病变。手术后五年，影像学检查和他的CEA水平均正常，疗效得以维持。即使对于右结肠癌，如果RAS是野生型，抗表皮生长因子受体（EGFR）抗体可能也有效。
